Smith & Nephew SNATS, Inc. (NYSE:SNN) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Analyst consensus is “Hold”: Of 12 analysts covering Smith & Nephew SNATS, 10 recommend holding, one rates it a sell, and one recommends buying. The average 12-month price target is $31.91.
• Several firms recently became more cautious, including Morgan Stanley, Kepler Capital Markets, and Bank of America, which downgraded the stock or initiated neutral ratings.
• SNN opened at $27.66, near its 52-week low of $27.23, while institutional investors and hedge funds own approximately 25.64% of the company.

Shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Get Free Report) have earned an average recommendation of "Hold" from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have given a hold rating and one has issued a buy rating on the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $31.91.

Several research analysts recently weighed in on SNN shares. JPMorgan Chase & Co. restated a "neutral" rating on shares of Smith & Nephew SNATS in a research report on Thursday, August 6th. Morgan Stanley cut Smith & Nephew SNATS from an "overweight" rating to an "equal weight" rating in a report on Wednesday, September 2nd. BTIG Research started coverage on Smith & Nephew SNATS in a research note on Monday, August 31st. They set a "neutral" rating for the company. Kepler Capital Markets cut Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a report on Thursday, June 4th. Finally, Bank of America downgraded Smith & Nephew SNATS from a "buy" rating to a "neutral" rating in a research report on Tuesday, September 8th.

Smith & Nephew SNATS Stock Up 0.4%

NYSE:SNN opened at $27.66 on Tuesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 2.14. Smith & Nephew SNATS has a fifty-two week low of $27.23 and a fifty-two week high of $37.51. The company has a fifty day moving average of $29.62 and a two-hundred day moving average of $30.77.

Smith & Nephew SNATS Announces Dividend

The company also recently disclosed a dividend, which will be paid on Friday, November 6th. Investors of record on Friday, October 2nd will be paid a $0.312 dividend. This represents a yield of 205.0%. The ex-dividend date of this dividend is Friday, October 2nd.

Institutional Investors Weigh In On Smith & Nephew SNATS

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Sequoia Financial Advisors LLC grew its holdings in shares of Smith & Nephew SNATS by 31.4% during the second quarter. Sequoia Financial Advisors LLC now owns 17,466 shares of the medical equipment provider's stock worth $503,000 after buying an additional 4,174 shares in the last quarter. Tidal Investments LLC lifted its stake in shares of Smith & Nephew SNATS by 60.2% in the second quarter. Tidal Investments LLC now owns 267,513 shares of the medical equipment provider's stock worth $7,707,000 after buying an additional 100,565 shares in the last quarter. WINTON GROUP Ltd acquired a new position in Smith & Nephew SNATS during the second quarter worth about $510,000. Engineers Gate Manager LP boosted its position in Smith & Nephew SNATS by 26.4% during the second quarter. Engineers Gate Manager LP now owns 13,002 shares of the medical equipment provider's stock worth $375,000 after acquiring an additional 2,714 shares during the last quarter. Finally, Allworth Financial LP grew its stake in Smith & Nephew SNATS by 94.8% during the 2nd quarter. Allworth Financial LP now owns 2,965 shares of the medical equipment provider's stock valued at $85,000 after acquiring an additional 1,443 shares in the last quarter. Institutional investors and hedge funds own 25.64% of the company's stock.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc is a global medical technology company headquartered in the United Kingdom. Founded in 1856 by Thomas James Smith in Hull, the company initially operated as a pharmacy business before expanding into healthcare products and medical devices.

The company develops and manufactures technologies used in orthopaedic reconstruction, sports medicine, and advanced wound management. Its products include joint replacement systems, trauma and extremities devices, arthroscopic equipment, surgical repair technologies, wound dressings, negative-pressure wound therapy systems, and other products designed to support tissue healing and surgical care.

Smith & Nephew serves hospitals, healthcare professionals, and patients in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.